IOL Chemicals & Pharmaceuticals Gears Up for Q3 Reveal on 11th February; Check Key Expectations Here

February 10, 2026
Posted by: Ekta Dhawan
Category: News

Click and Sign Up to Get Live Updates on Q3 Results

IOL Chemicals & Pharmaceuticals Q3 results FY26 are scheduled to be announced on 11th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

IOL Chemicals & Pharmaceuticals Q3 Results 2026 Preview

IOL Chemicals & Pharmaceuticals’ revenue is expected to be in the range of ₹523.30 crore, a 0.47% YoY decrease.
Profit After Tax, or PAT, is projected to rise 7.21% YoY.
Net profit is ₹20.53 crore, up 7.21% YoY
EBITDA to rise 19.30%

IOL Chemicals & Pharmaceuticals Share Performance

Over the past six months, IOL Chemicals & Pharmaceuticals’ share price has risen by 15.09% to ₹575.15.
Moreover, over the past year, the stock has increased by 14.83%.
Despite this weak short-term performance, IOL Chemicals & Pharmaceuticals’ stock has delivered a financially sound 217.06% return over the past 5 years.
As of 10th February 2026, the stock traded at ₹575.15 per share.

Key Factors to Watch for IOL Chemicals & Pharmaceuticals Q3 Results FY26

Revenue Growth & Segment Trends: Performance of pharmaceutical APIs and speciality chemicals, including exports.
Profitability & Margins: EBITDA and PAT margins are impacted by pricing, costs, and operational efficiency.
Product Mix & Diversification: Contribution from high-value APIs versus commodity products and non-Ibuprofen portfolio expansion.
Capacity Utilisation & Regulatory Approvals: Impact of new capacity ramp-ups and approvals supporting export growth.
Cost Control & Balance Sheet: Management of input and energy costs, working capital, and financial flexibility.

Final Thoughts

IOL Chemicals & Pharmaceuticals will announce its Q3 FY26 results on 11th February 2026. Analysts expect 0.47% revenue growth, a 7.21% rise in PAT, and a 19.30% rise in EBITDA. IOL Chemicals & Pharmaceuticals focuses growth in API and specialty chemical sales, margin trends, product diversification beyond Ibuprofen, capacity utilisation with regulatory approvals, and cost & balance sheet management.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%

Salora International Q3 Results FY26 Preview: PAT falls 18.54%

Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%

AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%

Glance Finance Q3 Results FY26 Preview: PAT rises 58.48%

Q3 Results Q3 Results 2026

Author: Ekta Dhawan

Ekta Dhawan is a Financial Content Writer at Univest, covering Indian equity markets with a focus on stock analysis, IPOs, and quarterly earnings results. Over 2+ years, she has published 1500+ articles tracking listed companies across sectors, translating complex financial data into clear, actionable insights for retail investors. She holds a Bachelor of Business Administration (BBA) and a Post Graduate Diploma in Management (PGDM), giving her a structured grounding in corporate finance, equity valuation, and capital markets. Her writing moves past surface-level reporting to explain why a stock is moving, what a quarterly result signals, and how investors should interpret it. She also brings expertise in SEO content strategy, keyword research, and on-page optimisation, ensuring articles reach investors actively searching for clarity on market events. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.